RayOne EMV (Rayner) Receives Health Canada Approval

Posted on 23/01/2024

Mississauga, ON, 23 January 2024

Rayner, a global leader in products for cataract surgery, proudly announces the approval of RayOne EMV (RAO200E) by Health Canada1. Developed in collaboration with Professor Graham Barrett, RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration to slightly extend the depth of focus.

“I’ve been awaiting Health Canada approval of RayOne EMV since hearing about the great outcomes achieved by colleagues from around the world and am excited to begin offering it to my patients. RayOne EMV will be an important addition to our IOL armamentarium for patients desiring spectacle independence beyond a standard monofocal,” said Dr. Paul Sanghera, cofounder of Lumea and Clarity Eye Institute.

Since the launch of RayOne EMV in 2020, clinical data has consistently demonstrated that RayOne EMV provides high quality vision2. Unlike some IOLs which utilize diffraction to increase depth of focus, the carefully controlled positive spherical aberration induced by RayOne EMV spreads light along the visual axis. To date, over 335,000 RayOne EMVs have been successfully implanted worldwide, demonstrating its widespread popularity and success.

“Many patients are seeking opportunities to receive high quality vision without side effects, and I believe that RayOne EMV will offer a compelling solution for many of them,” reported Dr. Louis Racine of the Centre Hospitalier de l’Université de Montréal.

Rayner has a rich history of innovation and a commitment to improving the lives of cataract patients since manufacturing the world’s first intraocular lens (IOL) in 1949. The introduction of RayOne EMV in Canada underscores Rayner’s dedication to advancing ophthalmic care and providing Canadian patients with access to new technology.


Rayner’s mission is to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients. Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals, and digital solutions worldwide in over 80 countries through a network of distributors and includes direct sales teams in the United Kingdom, USA, Canada, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.

Not all Rayner products are approved for sale in every country. Please contact your local Rayner representative for details of which products are available in your area.


©2024 Rayner Group, all rights reserved. Rayner and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner Surgical Corp, 75 Aventura Court, Mississauga, Ontario, L5T 2Y6. Registered in England: 615539. EC 2024-07 01/24

For further information and media enquiries, please contact Rayner: marketingteam@rayner.com

1. Medical Device License available upon request. 2. Ferreira TB. Comparison of visual outcomes of a Monofocal, two advanced Monofocal and two extended depth of focus intraocular lenses. Presented at ESCRS 2022.

Share this article